Phase I clinical trial of ShigETEC

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escherichia coli/Shigella oral vaccine-Eveliqur Biotechnologies (Primary)
Indications Traveller's diarrhoea
Focus Adverse reactions; First in man
Sponsors Eveliqure Biotechnologies

14 Sep 2020 New trial record
10 Sep 2020 According to an Eveliqure Biotechnologies media release, the company announced today the award of a grant from Horizon2020- the European Union's Research and Innovation programme that supports first-in-man studies of the ShigETEC vaccine. The project will run for 5 years and will cover the manufacture and formulation of clinical trial material and Phase 1 safety and immunogenicity studies in two different populations, adults in Europe and children in Bangladesh.
09 Sep 2020 According to an Eveliqure Biotechnologies pipeline, this trial is due to start in H1 2020. (https://www.eveliqure.com/strategy)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com